Ibiglustat | Genz-682452 | GZ402671 | GZ-452 | CAS#1401090-53-6 | 1629063-78-0

MedKoo Cat#: 319547 | Name: Ibiglustat

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Venglustat, also known as Ibiglustat, GZ402671, GZ-452; Genz-682452 and SAR402671, is a potent and selective Glucosylceramide synthase inhibitor and ceramide glucosyltransferase inhibitor. Ibiglustat blocks the formation of glucosylceramide (GL-1), a key intermediate in the synthesis of GL-3. Ibiglustat is potentially useful for treating Fabry disease. Fabry disease is a rare lysosomal storage disorder, which results in abnormal tissue deposits of a particular fatty substance called globotriaosylceramide (GL-3 or Gb3) throughout the body.

Chemical Structure

Ibiglustat

CAS#1401090-53-6 (free base)

Theoretical Analysis

MedKoo Cat#: 319547

Name: Ibiglustat

CAS#: 1401090-53-6 (free base)

Chemical Formula: C20H24FN3O2S

Exact Mass: 389.1573

Molecular Weight: 389.49

Elemental Analysis: C, 61.68; H, 6.21; F, 4.88; N, 10.79; O, 8.22; S, 8.23

Price and Availability

Size	Price	Availability
10mg	USD 150.00	Ready to ship
50mg	USD 450.00	Ready to ship
100mg	USD 750.00	Ready to ship
200mg	USD 1,250.00	Ready to ship
500mg	USD 2,450.00	Ready to ship
1g	USD 3,650.00	Ready to ship
2g	USD 6,450.00	Ready to ship

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

1401090-53-6 (free base) 1629063-79-1 (HCl) 1629063-80-4 (succinic acid) 1629063-78-0 (malate)

Synonym

GZ-402671; GZ402671; GZ 402671; SAR402671; SAR-402671; SAR 402671; Genz-682452-AA; GZ-452; Genz-682452; Ibiglustat; Venglustat;

IUPAC/Chemical Name

(3S)-1-azabicyclo[2.2.2]octan-3-yl N-{2-[2-(4-fluorophenyl)- 1,3-thiazol-4-yl]propan-2-yl}carbamate

InChi Key

YFHRCLAKZBDRHN-MRXNPFEDSA-N

InChi Code

InChI=1S/C20H24FN3O2S/c1-20(2,17-12-27-18(22-17)14-3-5-15(21)6-4-14)23-19(25)26-16-11-24-9-7-13(16)8-10-24/h3-6,12-13,16H,7-11H2,1-2H3,(H,23,25)/t16-/m1/s1

SMILES Code

O=C(O[C@@H]1CN2CCC1CC2)NC(C)(C3=CSC(C4=CC=C(F)C=C4)=N3)C

Appearance

Solid powder

Purity

>97% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Related CAS# 1401090-53-6 1629063-78-0 (

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#S22S09C30

QC Data

View QC data: current batch, Lot#S22S09C30

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

Ibiglustat is a selective, allosteric inhibitor of glucosylceramide synthase (GCS) with ability to cross the blood-brain barrier.

In vitro activity:

TBD

In vivo activity:

TBD

	Solvent	mg/mL	mM
Solubility
	DMSO	37.5	96.28

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 389.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

TBD

In vitro protocol:

TBD

In vivo protocol:

TBD

1: Peterschmitt MJ, Saiki H, Hatano T, Gasser T, Isaacson SH, Gaemers SJM, Minini P, Saubadu S, Sharma J, Walbillic S, Alcalay RN, Cutter G, Hattori N, Höglinger GU, Marek K, Schapira AHV, Scherzer CR, Simuni T, Giladi N, Sardi SP, Fischer TZ; MOVES-PD Investigators. Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo- Controlled MOVES-PD Trial. J Parkinsons Dis. 2022;12(2):557-570. doi: 10.3233/JPD-212714. PMID: 34897099; PMCID: PMC8925113. 2: Viel C, Clarke J, Kayatekin C, Richards AM, Chiang MSR, Park H, Wang B, Shihabuddin LS, Sardi SP. Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model. Sci Rep. 2021 Oct 22;11(1):20945. doi: 10.1038/s41598-021-00404-5. PMID: 34686711; PMCID: PMC8536659. 3: Peng Y, Liou B, Lin Y, Fannin V, Zhang W, Feldman RA, Setchell KDR, Grabowski GA, Sun Y. Substrate Reduction Therapy Reverses Mitochondrial, mTOR, and Autophagy Alterations in a Cell Model of Gaucher Disease. Cells. 2021 Sep 2;10(9):2286. doi: 10.3390/cells10092286. PMID: 34571934; PMCID: PMC8466461. 4: Nicoli ER, Annunziata I, d'Azzo A, Platt FM, Tifft CJ, Stepien KM. GM1 Gangliosidosis-A Mini-Review. Front Genet. 2021 Sep 3;12:734878. doi: 10.3389/fgene.2021.734878. PMID: 34539759; PMCID: PMC8446533. 5: Vitner EB, Achdout H, Avraham R, Politi B, Cherry L, Tamir H, Yahalom-Ronen Y, Paran N, Melamed S, Erez N, Israely T. Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and influenza virus. J Biol Chem. 2021 Jan- Jun;296:100470. doi: 10.1016/j.jbc.2021.100470. Epub 2021 Feb 25. PMID: 33639165; PMCID: PMC7904475. 6: Wilson MW, Shu L, Hinkovska-Galcheva V, Jin Y, Rajeswaran W, Abe A, Zhao T, Luo R, Wang L, Wen B, Liou B, Fannin V, Sun D, Sun Y, Shayman JA, Larsen SD. Optimization of Eliglustat-Based Glucosylceramide Synthase Inhibitors as Substrate Reduction Therapy for Gaucher Disease Type 3. ACS Chem Neurosci. 2020 Oct 21;11(20):3464-3473. doi: 10.1021/acschemneuro.0c00558. Epub 2020 Oct 9. PMID: 33035424; PMCID: PMC7919060. 7: Schneider SA, Hizli B, Alcalay RN. Emerging Targeted Therapeutics for Genetic Subtypes of Parkinsonism. Neurotherapeutics. 2020 Oct;17(4):1378-1392. doi: 10.1007/s13311-020-00920-8. PMID: 32914362; PMCID: PMC7483040. 8: Peterschmitt MJ, Crawford NPS, Gaemers SJM, Ji AJ, Sharma J, Pham TT. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers. Clin Pharmacol Drug Dev. 2021 Jan;10(1):86-98. doi: 10.1002/cpdd.865. Epub 2020 Aug 26. PMID: 32851809; PMCID: PMC7818513. 9: van der Veen SJ, Hollak CEM, van Kuilenburg ABP, Langeveld M. Developments in the treatment of Fabry disease. J Inherit Metab Dis. 2020 Sep;43(5):908-921. doi: 10.1002/jimd.12228. Epub 2020 Mar 2. PMID: 32083331; PMCID: PMC7540041. 10: Schneider SA, Alcalay RN. Precision medicine in Parkinson's disease: emerging treatments for genetic Parkinson's disease. J Neurol. 2020 Mar;267(3):860-869. doi: 10.1007/s00415-020-09705-7. Epub 2020 Jan 23. PMID: 31974807; PMCID: PMC7035220. 11: Marshall J, Nietupski JB, Park H, Cao J, Bangari DS, Silvescu C, Wilper T, Randall K, Tietz D, Wang B, Ying X, Leonard JP, Cheng SH. Substrate Reduction Therapy for Sandhoff Disease through Inhibition of Glucosylceramide Synthase Activity. Mol Ther. 2019 Aug 7;27(8):1495-1506. doi: 10.1016/j.ymthe.2019.05.018. Epub 2019 Jun 4. PMID: 31208914; PMCID: PMC6697407. 12: Marshall J, Sun Y, Bangari DS, Budman E, Park H, Nietupski JB, Allaire A, Cromwell MA, Wang B, Grabowski GA, Leonard JP, Cheng SH. CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease. Mol Ther. 2016 Jun;24(6):1019-1029. doi: 10.1038/mt.2016.53. Epub 2016 Mar 7. PMID: 26948439; PMCID: PMC4923322. 13: Ashe KM, Budman E, Bangari DS, Siegel CS, Nietupski JB, Wang B, Desnick RJ, Scheule RK, Leonard JP, Cheng SH, Marshall J. Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease. Mol Med. 2015 Apr 30;21(1):389-99. doi: 10.2119/molmed.2015.00088. PMID: 25938659; PMCID: PMC4559530.

Morrison TA, Vigee J, Tovar KA, Talley TA, Mujal AM, Kono M, Philips R, Nagashima H, Brooks SR, Dada H, Rozich I, Hudspeth K, Lau CM, Yao C, Sciumè G, Sun HW, Bonifacino JS, Kanno Y, Dustin ML, Randazzo D, Proia RL, Sun JC, Shih HY, O'Shea JJ. Selective requirement of glycosphingolipid synthesis for natural killer and cytotoxic T cells. Cell. 2025 Apr 25:S0092-8674(25)00409-X. doi: 10.1016/j.cell.2025.04.007. Epub ahead of print. PMID: 40306279.